GlassScriptPhysician profile
Anne Rao
NPI 1356504245
$2,289.01
in general payments reported to CMS, 2019-2025
17 companies · $331 in 2025
The $331 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $231 · 2021: $354 · 2022: $215 · 2023: $440 · 2024: $519 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $344.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $321.71 | 2019-2025 | Gardasil 9, Rotateq, Vaxneuvance |
| Corium, LLC | $248.11 | 2023-2025 | Azstarys |
| Cranial Technologies, INC | $230.70 | 2019-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $214.87 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $204.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.29 | 2020-2022 | |
| Glaxosmithkline, LLC. | $198.04 | 2019-2024 | Flulaval Quadrivalent, Fluarix Quadrivalent, Bexsero |
| Supernus Pharmaceuticals, INC. | $79.19 | 2021-2023 | Qelbree |
| Seqirus USA INC | $52.47 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Kowa Pharmaceuticals America, INC. | $47.02 | 2025 | Zoryve |
| Kaleo, INC. | $45.18 | 2021 | |
| Vertical Pharmaceuticals, LLC | $39.35 | 2019-2024 | Relexxii |
| Tris Pharma INC | $20.32 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.80 | 2024 | Crysvita |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $14.92 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $14.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.